Abstract: Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.
INTRODUCTION
Solar urticaria (SU) is a rare photodermatosis characterized by rapid induction of symptoms and onset of skin lesions after exposure to sunlight. The pathogenesis of the disease has yet not been fully elucidated. Currently, the onset of symptoms is considered to be triggered by a yet to be identified chromophore, which is activated by light of a particular wavelength. 1 The diagnostic process is based on the characteristic clinical history, completed by phototesting to determine the specific wavelength, the triggering spectrum of the light, responsible for the symptoms. Visible light and UVA rays are the most frequently involved. 2 Solar urticaria has a significant impact on the quality of life of patients, therefore requiring an effective therapy. However, the treatment is challenging and the combination of several therapeutic modalities is almost always necessary. 1, 3 Recently, some cases of US with successful treatment with omalizumab have been published. been several cases recently reported of its efficacy also in patients with SU. To date, 20 articles have been published, the majority being case reports or small case series and one multicentric prospective study in France. [6] [7] [8] Forty-five cases of SU treated with omalizumab (including the patient presented in this case report) were identified. In 36 patients (80%), the symptoms were controlled successfully. In 9 cases (20%), the treatment response was partial or insufficient. The treatment schemes differ from patient to patient, with maintenance dosage 150-450 mg every 2 weeks or monthly. 4 In the presented case, we adopted the dosing as indicated for CSU, with an excellent response.
Further studies are warranted to establish the correct therapeutic scheme, but certainly omalizumab will remain a valid and useful option, due to its efficacy and safety profile presented so far.q
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